01 Growing Adoption of Multi-Cancer Blood Testing The cancer diagnostics market is increasingly moving toward blood-based tests designed to identify signals associated with several cancers from a single sample. These assays analyze circulating molecular information and can complement conventional organ-specific screening by providing a broader approach to early detection. Their development is particularly important for cancers that currently lack routine population screening pathways. Multi-cancer blood testing is therefore becoming an important part of cancer diagnostics market trends. In June 2026, GRAIL expanded its Galleri multi-cancer early detection program following analysis involving more than 25,000 participants. The blood test is designed to detect signals associated with more than 50 cancer types and predict the cancer signal's tissue of origin.
02 Increasing Integration of AI Into Digital Pathology AI algorithms can identify suspicious regions, quantify tissue characteristics, and prioritize slides for review while pathologists retain responsibility for diagnosis. This approach can reduce repetitive visual assessment and help standardize interpretation across large case volumes. AI-assisted pathology is consequently expanding the cancer diagnostics industry toward computational tissue analysis. In March 2025, Paige received regulatory authorization for an AI application supporting prostate-cancer pathology. The technology was developed using a dataset containing more than 3 million digitized pathology slides to support AI-based cancer assessment.
01 Expansion of Precision Oncology Increases Biomarker Testing Requirements Cancer treatment is increasingly determined by specific molecular characteristics rather than tumor location alone. Clinicians therefore need diagnostic tests capable of identifying mutations, gene fusions, expression patterns, and other biomarkers before selecting targeted therapies. Precision medicine is therefore strengthening cancer diagnostics market demand. In May 2026, Foundation Medicine expanded FoundationOne Liquid CDx with additional biomarker and therapy-related capabilities.
01 High Cost of Advanced Molecular Testing Can Limit Patient Access Comprehensive genomic profiling, liquid biopsy, and other advanced diagnostic methods require sophisticated sequencing platforms, specialized reagents, bioinformatics infrastructure, and trained laboratory personnel. Limited reimbursement can further discourage routine use when the clinical benefit is uncertain for a specific patient. Affordability can consequently restrain cancer diagnostics market growth.
01 Expansion of Minimal Residual Disease Testing Minimal residual disease testing provides a distinct opportunity by detecting traces of cancer that may remain after surgery or other treatment even when conventional imaging shows no visible disease. MRD testing can therefore help providers increase cancer diagnostics market share.
01 Obtaining Adequate Tumor Material for Reliable Testing Many patients have small tumors, inaccessible lesions, or biopsy samples containing limited quantities of malignant tissue. Repeated invasive biopsies can also be difficult when disease progresses or treatment decisions require updated molecular information. Sample adequacy therefore remains a major challenge as cancer diagnostics market size expands toward increasingly detailed molecular analysis. The assay analyzes circulating tumor DNA across more than 100 genes, providing an alternative molecular-testing pathway when obtaining sufficient tumor tissue is difficult.
June 2026 Roche expanded its cancer diagnostics portfolio by advancing companion diagnostics, digital pathology, and molecular testing solutions. The company focused on improving precision oncology workflows and enabling more personalized treatment decisions through advanced biomarker analysis.
May 2026 Illumina expanded its next-generation sequencing (NGS) capabilities for oncology applications by advancing genomic profiling solutions. The initiatives focused on supporting precision cancer diagnosis, biomarker identification, and targeted therapy selection.
April 2026 Thermo Fisher Scientific expanded its oncology diagnostics portfolio through advancements in molecular testing, genomic analysis, and companion diagnostic technologies. The company focused on improving access to precision medicine solutions for cancer patients.
November 2025 Guardant Health expanded its liquid biopsy technology portfolio by advancing blood-based cancer testing solutions. The company focused on improving early detection, treatment monitoring, and genomic profiling for oncology applications.